Comparison
Epitalon vs Semaglutide
Side-by-side of Epitalon and Semaglutide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Epitalon
Epitalon peptide (Epithalon, tetrapeptide AEDG): telomerase activation, lifespan extension data, anti-aging trials, dosage, half-life, and safety.
Semaglutide
Semaglutide for weight loss: GLP-1 agonist (Ozempic, Wegovy) drives 15-17% mean loss at 2.4 mg/week in STEP trials. Watch lean-mass loss.
Effects at a glance
Epitalon
- •Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- •Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- •Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- •Independent Western replication is essentially absent; no FDA-standard RCTs
- •Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- •Not currently on the WADA Prohibited List
Semaglutide
- •Long-acting GLP-1 receptor agonist with a ~7-day half-life that supports once-weekly subcutaneous dosing
- •STEP trials reported ~15 to 17% mean body-weight loss at 2.4 mg/week over 68 weeks in adults with obesity
- •Lowers HbA1c by ~1.0 to 1.8 percentage points in type 2 diabetes versus placebo
- •SELECT trial showed reduced major cardiovascular events in adults with prior CVD and overweight or obesity
- •Up to 25 to 40% of weight lost can be lean mass; pairing with resistance training and protein intake mitigates this
- •GI effects (nausea, vomiting, constipation) drive most discontinuations and ease with slow titration
Side-by-side
| Attribute | Epitalon | Semaglutide |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | Epithalon, Ala-Glu-Asp-Gly, AEDG, Epithalamin (precursor extract) | Ozempic, Wegovy, Rybelsus |
| Half-life (hr) ↗ | 0.5 | 168 |
| Typical dose (mg) ↗ | 5 | 2.4 |
| Dosing frequency | daily during cycle | weekly (SC); daily (oral Rybelsus) |
| Routes | subcutaneous, intramuscular, intranasal | subcutaneous, oral |
| Onset (hr) | 24 | 24 |
| Peak (hr) | 168 | 72 |
| Molecular weight | 390.35 | 4113.58 |
| Molecular formula | C14H22N4O9 | - |
| Mechanism | Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization. | Long-acting GLP-1 receptor agonist; potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic satiety centers. |
| Legal status | Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU | Prescription only (FDA-approved, EMA-approved) |
| WADA status | unknown | allowed |
| DEA / Rx | Not scheduled (research chemical) | Rx only (not a controlled substance); FDA-approved for type 2 diabetes (2017) and chronic weight management (2021) |
| Pregnancy | Insufficient data; not recommended | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 307297-39-8 | 910463-68-2 |
| PubChem CID | 219042 | 56843331 |
| Wikidata | Q5384126 | Q27089394 |
Safety profile
Epitalon
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Interactions
- melatonin: potential additive effect on circadian and pineal output; no controlled data(minor)
Semaglutide
Common side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
- fatigue
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Semaglutide comes out ahead for most readers on the criteria we weight: 2 catalogued goals, prescription-only, oral dosing, with a Tier-A outcome catalogued. Epitalon is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick Epitalon.
- → If your priority is sleep onset or sleep quality, pick Epitalon.
- → If your priority is metabolic health and glucose control, pick Semaglutide.
- → If your priority is fat loss, pick Semaglutide.
Edge case: If you cannot self-administer injections, Semaglutide is the only oral option in this pair.
Default choice: Semaglutide. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Epitalon only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Epitalon and Semaglutide?
Epitalon and Semaglutide differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Epitalon or Semaglutide?
Epitalon half-life is 0.5 hours; Semaglutide half-life is 168 hours.
Can you stack Epitalon with Semaglutide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper